Laurus Labs Ltd (LAURUSLABS) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Laurus Labs Ltd on NSE and BSE, with an AI summary of each filing.
Please see annexed enclosure.
Transcript · 03 Nov 2026, 5:04 pm
Please see enclosed annexure.
Audio / Video · 30 Oct 2026, 2:31 am
Laurus Labs Releases Q2 FY27 Earnings Conference Call Audio Recording Laurus Labs Limited has made available the audio recording of its Q2 FY27 results conference call held on 29th Oct'26. The submission complies with Regulations 30 and 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, following the company's prior earnings call intimation on 13th Oct'26. The link for the audio recording has been officially disclosed to the stock exchanges for investor and market access.
Please see enclosed annexure
Press Release · 29 Oct 2026, 9:06 pm
Laurus Labs Reports Strong Q2 FY27 Results and Expands CDMO Capabilities Laurus Labs reported strong Q2 FY27 financial results on 29th Oct'26, with revenue increasing 33% YoY to ₹2,206 Cr and net profit surging 126% YoY to ₹441 Cr. EBITDA rose 78% YoY to ₹762 Cr, with margins expanding 850 bps to 34.5%, driven by 75% YoY growth in the CDMO segment to ₹904 Cr. The company declared an interim dividend of ₹1.00 per share. Additionally, Laurus signed definitive agreements to acquire a 60% stake in Galenvs Sciences and 52% in SI &C Resins to enhance its oligonucleotide and peptide CDMO capabilities.
Please see enclosed annexure
Investor Presentation · 29 Oct 2026, 8:48 pm
Laurus Labs Reports Robust 1H FY27 Growth Driven by CDMO Expansion Laurus Labs delivered strong 1H FY27 results, with revenue rising 31% YoY to ₹4,233 Cr, EBITDA jumping 72% YoY to ₹1,406 Cr (margins expanded 780 bps to 33.2%), and net profit increasing 126% YoY to ₹809 Cr. Growth was powered by CDMO small molecules (+77% YoY to ₹1,710 Cr). For Q2 FY27, revenue reached ₹2,206 Cr (+33% YoY) and PAT hit ₹441 Cr (+126% YoY). The company announced strategic acquisitions—a 60% stake in Galenvs and 52% in SI &C Resins—to enhance oligonucleotide and peptide capabilities, backed by a planned >₹3,000 Cr capex over FY27–FY28.
Please see enclosed annexure
Dividend · 29 Oct 2026, 8:43 pm
Laurus Labs Approves 50% Interim Dividend for FY26-27 Laurus Labs' Board of Directors approved an interim dividend of Re 1.00 per equity share (50% on a face value of Rs 2.00 each) for FY26-27 at its meeting on 29th Oct'26. The company has fixed 6th Nov'26 as the record date to determine eligible shareholders. The interim dividend will be disbursed on or after 19th Nov'26.
Appointment of Mr. Kundan Kumar Jha as Joint Company Secretary of the Company w.e.f. November 1, 2026
Others (Uncategorized) · 29 Oct 2026, 8:39 pm
Laurus Labs Appoints Kundan Kumar Jha as Joint Company Secretary Laurus Labs Limited's Board of Directors has approved the appointment of Mr. Kundan Kumar Jha as Joint Company Secretary and Key Managerial Personnel, effective 1st Nov'26, as part of the company's succession planning process. Mr. Jha brings over 23 years of experience in corporate governance, regulatory compliance, legal affairs, and M&A under SEBI and SEC regulations. He previously served as Company Secretary and Head of Legal at Cohance Lifesciences Limited, with prior tenures at Dr. Reddy's Laboratories, Rupa & Company, and Balrampur Chini Mills.
Please see enclosed annexure
Outcome · 29 Oct 2026, 8:37 pm
Laurus Labs Reports Strong Q2 FY27 Earnings and Declares Interim Dividend Laurus Labs reported strong Q2 FY27 consolidated revenue from operations of ₹2,206.37 crore, rising 33.4% YoY and 8.9% QoQ. Consolidated net profit surged 124.3% YoY to ₹436.19 crore, with diluted EPS expanding to ₹8.16 from ₹3.61 in Q2 FY26. For H1 FY27, revenue reached ₹4,232.68 crore with net profit of ₹798.26 crore. Operating cash flow stood at ₹804.96 crore for H1 FY27. Additionally, the Board declared an interim dividend of ₹1.00 per share (50%), setting 6th Nov'26 as the record date.
Please see enclosed annexure
Others (Uncategorized) · 29 Oct 2026, 8:35 pm
Laurus Labs Acquires 52% Stake in SI&C Resins for Rs 32.50 Crore Laurus Labs approved the primary acquisition of a 52% stake in SI & C Resins Private Limited (SI&C) for Rs 32.50 Cr at a pre-money valuation of Rs 30 Cr on 29th Oct'26. The company may invest an additional Rs 30 Cr in SI&C securities based on future funding needs. The cash transaction supports Laurus Labs' strategy to build fully integrated peptide manufacturing capabilities by securing domestic supplies of polymer- and silica-based resins and chromatography gels. SI&C will become a subsidiary upon deal completion in FY27.
Please see annexed enclosure
Others (Uncategorized) · 29 Oct 2026, 8:33 pm
Laurus Labs Acquires 60% Stake in Canada-Based Galenvs Sciences for USD 3.75 Million Laurus Labs' board approved acquiring a 60% stake in Canada-based CRO/CDMO Galenvs Sciences Inc. at a pre-money valuation of USD 3.50 million. The total cash investment of USD 3.75 million comprises a USD 2.75 million primary infusion (44% diluted stake) and a USD 1.00 million secondary purchase (16% diluted stake). Galenvs specializes in custom oligonucleotide synthesis and magnetic-nanoparticle technologies, clocking CY25 revenue of CAD 1.65 million. The deal bolsters Laurus Labs' oligonucleotide R&D pipeline and expands its North American footprint.
Please see annexed enclosure
Financial Result · 29 Oct 2026, 8:30 pm
Laurus Labs Reports Strong Q2 FY27 Results; Declares Interim Dividend Laurus Labs posted consolidated revenue from operations of ₹2,206.37 crore for the quarter ended 30th Sep'26, up 33.4% YoY and 8.9% QoQ. Consolidated net profit attributable to equity holders surged 126.4% YoY to ₹441.48 crore, compared to ₹194.97 crore in 30th Sep'25, with basic EPS rising to ₹8.17 from ₹3.61. Profit before tax stood at ₹591.82 crore versus ₹269.73 crore YoY. The Board declared an interim dividend of ₹1.00 per share (50%), fixing 6th Nov'26 as the record date.
Laurus Labs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 29 Oct 2026, 8:25 pm
Laurus Labs Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore) ■ Revenue: 2,206 (+33.4% YoY | +8.9% QoQ) ■ EBITDA: 750 (+86.1% YoY | +17.6% QoQ) ■ EBITDA Margin (%): 34.0 (+962 bps YoY | +251 bps QoQ) ■ PAT: 441 (+126.4% YoY | +20.1% QoQ) ■ EPS (INR): 8.16 (+126.0% YoY | +20.0% QoQ)
Please see annexed enclosure.
Others (Uncategorized) · 15 Oct 2026, 2:17 am
CARE ESG Ratings Assigns 'CareEdge-ESG 1+' Rating to Laurus Labs CARE ESG Ratings assigned an ESG rating to Laurus Labs on 14th Oct'26, awarding a score of 82.6 with the rating symbol 'CareEdge-ESG 1+'. The assigned rating signifies a leadership position in managing ESG risks through best-in-class disclosures, policies, and operational performance.
Please see annexed enclosure.
Others (Uncategorized) · 15 Oct 2026, 1:39 am
Laurus Labs Invests INR 1,078 Mn in KRKA Pharma via Rights Issue Laurus Labs Limited has invested INR 1,078 Mn to acquire 107.8 Mn equity shares of KRKA Pharma Private Limited at a face value of INR 10 per share via a rights issue, following its prior intimation on 30th Apr'26. KRKA Pharma operates as a joint venture between KRKA d.d., Novo mesto, Slovenia, and Laurus Labs. Post-transaction, Laurus Labs' total holding increases to 262.15 Mn equity shares, maintaining its equity stake unchanged at 49%.
LAURUS LABS LIMITED has informed the Exchange about Board Meeting to be held on 29-Oct-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Dividend.
Intimation · 29 Oct 2026, 5:30 am
Please see annexed enclosure.
Intimation · 29 Oct 2026, 5:00 pm
Laurus Labs Schedules Q2 & H1 FY27 Earnings Call for 29th Oct'26 Laurus Labs Ltd announced it will host its Q2 & H1 FY27 earnings conference call on 29th Oct'26 at 5:00 PM IST, organized by DAM Capital Advisors to discuss financial performance followed by an interactive Q&A session. Primary dial-in access is available via +91 22 6280 1384 and +91 22 7115 8285, alongside dedicated toll-free lines for key international markets including the US, UK, Singapore, and Hong Kong. Laurus generated ₹6,813 crore in annual revenue in FY26.
Laurus Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve the un-audited financial results ....
Intimation · 29 Oct 2026, 5:30 am
Laurus Labs Schedules Board Meeting for Q2 FY27 Results and Interim Dividend Laurus Labs Limited announced that its Board of Directors will meet on 29th Oct'26 to consider and approve the un-audited financial results for the quarter and half-year ended 30th Sep'26. Additionally, the board will evaluate a proposal for the payment of an interim dividend for FY 2026-27 and fix the record date to determine shareholder eligibility, if approved. The company's trading window for designated persons remains closed from 1st Oct'26 through 31st Oct'26.
To consider and approve the financial results for the period ended September 30, 2026 and dividend
Intimation · 29 Oct 2026, 5:30 am
Please see annexed enclosure.
Others (Uncategorized) · 06 Oct 2026, 11:36 pm
Laurus Labs Invests INR 12.1 Crore in Associate Kurnool Renewables via Rights Issue Laurus Labs has invested INR 12.10 Cr to acquire 1.21 Cr equity shares of its associate company, Kurnool Renewables Private Limited (KRPL), at a face value of INR 10 per share through a rights issue on 6th Oct'26. Following this transaction, Laurus Labs' total holding in KRPL increases to 2.12 Cr equity shares, while its overall equity stake in the associate remains unchanged at 26%.
Please see attached enclosure.
Investor Presentation · 18 Sept 2026, 11:51 pm
Laurus Labs Delivers Strong 1QFY27 Operating Performance Driven by CDMO Expansion Laurus Labs reported strong 1QFY27 revenue of ₹2,026 Cr (up 29% YoY, 12% QoQ), led by robust CDMO growth. EBITDA rose 66% YoY to ₹644 Cr with margins expanding 700 bps YoY to 31.8%, driven by an improved mix and operating leverage. Net profit surged 126% YoY to ₹368 Cr. The company is executing a >₹3,000 Cr capex plan across FY27-FY28, allocating >85% toward growth in CDMO, fermentation, peptides, and advanced biologics. Management guides for sustained >30% EBITDA margins from FY27 onward.
Please see annexed enclosure.
Intimation · 15 Sept 2026, 10:59 pm
Laurus Labs to Attend Goldman Sachs Global Healthcare CDMO Day Laurus Labs Limited announced its participation in the Goldman Sachs Global Healthcare CDMO Day from 22nd Sep'26 to 24th Sep'26 in Singapore. The company will engage in in-person interactions, comprising both one-on-one and group meetings with analysts and institutional investors. The management confirmed that no unpublished price-sensitive information will be shared during these scheduled sessions.
Please see annexed enclosure.
Intimation · 10 Sept 2026, 6:27 pm
Laurus Labs Schedules Group Investor Meeting on 17th Sep'26 Laurus Labs Limited announced an in-person group investor meeting scheduled for 17th Sep'26 in Hyderabad, organized by ICICI Securities. The disclosure, made pursuant to Regulation 30 of SEBI LODR Regulations, confirms that no Unpublished Price Sensitive Information will be shared during the interactions. The meeting schedule remains subject to change based on operational exigencies from either the investors or the company.
Please see annexed enclosure.
Intimation · 31 Aug 2026, 9:04 pm
Laurus Labs to Participate in Antique Pharma Investor Day Laurus Labs (NSE: LAURUSLABS) announced its participation in the Antique Pharma Investor Day. The in-person group meeting is scheduled for 07 Sep'26 in Hyderabad. The company confirmed that no Unpublished Price Sensitive Information (UPSI) will be disclosed during the event. The date is subject to change based on exigencies from investors or the company.
Please see annexed enclosure.
Intimation · 12 Aug 2026, 11:50 pm
Laurus Labs to Participate in Motilal Oswal Investor Conference Laurus Labs will participate in the Motilal Oswal 22nd Annual Global Investor Conference on 19 Aug'26. The company will engage in one-on-one and group in-person meetings with analysts and institutional investors in Mumbai. Laurus Labs has confirmed that no Unpublished Price Sensitive Information (UPSI) will be disclosed during the event. The meeting schedule remains subject to potential changes.
Please see annexed enclosure.
Others (Uncategorized) · 11 Aug 2026, 1:01 am
Laurus Labs Receives an ESG Score of 63/100 from NSE Sustainability Laurus Labs announced on 10 Aug'26 that NSE Sustainability Ratings and Analytics Limited has independently assigned it an Environmental, Social, and Governance (ESG) Score of 63 out of 100 for FY 2026. Laurus Labs clarified that it did not engage NSE for this rating and the score was prepared independently by NSE based on publicly available data.
Please see annexed enclosure.
Transcript · 30 Jul 2026, 4:36 pm